Form 4: United Therapeutics EVP & General Counsel Executes Pre-Arranged Stock Option Exercise and Sale

Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp, completed a pre-arranged exercise of stock options and subsequent sale of common stock totaling 11,000 shares on June 26, 2025.

Summary

• Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp (UTHR), exercised 11,000 stock options at an exercise price of $135.42 per share on June 26, 2025.
• Concurrently, Mr. Mahon sold 11,000 shares of common stock resulting from the option exercise through multiple transactions on the same date.
• The sales were executed at weighted average prices ranging from $284.1029 to $288.8 per share.
• These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, which was entered into on December 24, 2024.
• Following these transactions, Mr. Mahon directly beneficially owns 36,781 shares of common stock and 121,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, it's a pre-planned transaction (10b5-1 plan) for option exercise and sale, which is a common practice for executives to manage their equity compensation and diversify holdings. The significant difference between exercise and sale prices indicates a positive return for the executive.

Positives

• The exercise of stock options indicates that the executive is realizing value from their compensation, which can be seen as a positive sign of the company's performance over time.
• The sale prices of the common stock (ranging from $284.1029 to $288.8) are significantly higher than the exercise price of the options ($135.42), indicating a substantial gain for the executive.

Negatives

• The sale of shares by an insider, even if pre-planned, can sometimes be perceived as a reduction in their direct equity stake, although in this case, it appears to be a routine exercise-and-sell transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitors, beyond the context of executive compensation practices within the pharmaceutical/biotechnology sector.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a pre-arranged plan, which typically has minimal impact on shareholder sentiment. It demonstrates an executive realizing value from their compensation.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Executive Compensation, Paul A. Mahon